What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GHRH analog · approved for HIV-associated lipodystrophy
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Tesamorelin inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Tesamorelin is a synthetic 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoyl modification that protects the molecule from DPP-4 cleavage and extends the plasma half-life relative to native GHRH or unmodified Sermorelin. It is the only FDA-approved member of the GHRH-analog class, indicated as a finished drug (Egrifta) for HIV-associated lipodystrophy and the reduction of excess visceral abdominal fat in HIV-positive patients with lipodystrophy. PeptideXpo supplies Tesamorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The 44-residue sequence is at the upper-middle range for SPPS, and the analytical packet emphasizes peak-integration HPLC plus ESI mass spec confirming the N-terminal hexenoyl modification, the modified mass is the diagnostic identity check. Sequence verification by LC-MS/MS is available on request and is recommended at first-time supplier qualification because the hexenoyl group's positional integrity matters for biological activity. Tesamorelin is most commonly ordered as the standalone vial for visceral-fat research and compounding workflows, or as the pre-blended Tesamorelin + Ipamorelin combination (the tesa-ipa-blend SKU) for dual-pathway GH-axis research.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
The finished Tesamorelin drug (Egrifta) is FDA-approved for HIV-associated lipodystrophy. The bulk active itself is not on the 503A bulks list; compounding eligibility for off-label or other indications depends on the destination market's current shortage / regulatory posture.
Frequently asked questions
Tesamorelin is the only FDA-approved GHRH analogue as a finished drug, distinguishing it from Sermorelin (which had a now-discontinued approval), CJC-1295 (no approval), and Modified GRF 1-29 (no approval). Mechanistically, Tesamorelin's N-terminal trans-3-hexenoyl modification gives it both better protease resistance than unmodified Sermorelin and a half-life roughly similar to CJC-1295 no-DAC, but at lower mass-equivalent because the hexenoyl group is a small modification rather than the larger substitutions used in CJC-1295. Tesamorelin's specific clinical context, visceral-fat reduction in HIV-associated lipodystrophy, drove most of the rigorous PK and clinical-outcome data in this family.
For first-time supplier qualification of Tesamorelin, request: (1) HPLC chromatogram with peak integration showing ≥99.0% main-peak area, (2) ESI mass spec confirming the modified mass (≈5135.8 Da for Tesamorelin vs. ≈3358 Da for unmodified Sermorelin 1-29, the mass difference is diagnostic of the hexenoyl modification, but it's also worth confirming the modified peak is the dominant species), (3) LC-MS/MS sequence verification covering the N-terminal residues to confirm the hexenoyl is positioned correctly, and (4) water content + counter-ion. For 503A-style compounding workflows add LAL endotoxin and USP <61>/<62> microbial limits.
Yes, the GHRH-receptor agonist plus GHSR agonist combination strategy applies equally to Tesamorelin. PeptideXpo supplies pre-blended co-lyophilized Tesamorelin + Ipamorelin vials under the tesa-ipa-blend SKU at standard 10+5 mg total ratios (custom ratios via OEM service). The mechanistic rationale matches the CJC-1295 + Ipamorelin combination: two parallel input pathways converging on somatotroph GH release produce additive magnitudes beyond either component alone.
Related peptides
29-mer
GHRH 1-29 fragment
Modified GRF 1-29 · GHRH analog
GH-axis blend (Tesamorelin + Ipamorelin), 15 mg total
